The correlation between metabolic syndrome and the prostate volume

Korean Journal of Urology

Volumn 48, Issue 6, 2007, Pages 603-607

  Sohn, Jee Chul ^a   Chang, Hyuk Soo ^a   Kim, Chun Il ^a  

^a Keimyung University School of Medicine   (South Korea)

Author keywords

Benign prostatic hyperplasia; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ADULT; ANTIGEN DETECTION; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORGAN SIZE; OUTPATIENT; PROSTATE; PROSTATE HYPERTROPHY; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TRANSRECTAL ULTRASONOGRAPHY;

EID: 34347381717     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.6.603     Document Type: Article

References (29)

1. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39: 151-8
2. Michel MC, Heemann U, Schumacher H, Mehlburger L, Goepel M. Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol 2004;172:1390-3
3. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptoms and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001;2:297-301
4. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-62
5. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori 2004; 52:291-4
6. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29-36
7. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001; 39:151-8
8. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-203
9. Nandeesha H, Koner BC, Dorairajan LN, Sen SK. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta 2006;370:89-93
10. Kim JH, Shin BS, Kim JS, Hong YS. Voiding dysfunction of men is associated with metabolic syndrome. Korean J Urol 2006;47:257-62
11. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor's clothes fit? Diabetes Care 2004;27:1011-2
12. Ford ES. Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S. Diabetes Care 2005;28:2745-9
13. Lim S, Lee HK, Park KS, Cho SI. Changes in the characteristics of metabolic syndrome in Korea over the period 1998-2001 as determined by Korean National Health and Nutrition examination surveys. Diabetes Care 2005;28:1810-2
14. Timme TL, Truong LD, Merz VW, Krebs T, Kadmon D, Flanders KC, et al. Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology 1994;134:1039-45
15. Brochu M, Belanger A. Comparative study of plasma steroid and steroid glucuronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 1987;11:33-40
16. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994; 370:341-7
17. Zaroli A, Mandressi A, Belloni M, Antonelli D, Bernasconi S, Buizza C, et al. Physiopathology of BPH obstruction. Arch Ital Urol Androl 1995;67:13-6
18. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
19. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94
20. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J 1994;15 (Suppl C): 78-81
21. Landsberg L. Diet, obesity an hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptice thermogenesis. Q J Med 1986;61:1081-90
22. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia 1989;32(Suppl): 465A
23. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17:477-86
24. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and setum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604
25. Eldrup E, Lindholm J, Winkel P. Plasma sex hormones and ischemic heart disease. Clin Biochem 1987;20:105-12
26. Soygur T, Kupeli B, Aydos K, Kupeli S, Arikan N, Muftuoglu YZ, et al. Effect of obesity on prostatic hyperplasia: its relation to sex steroid levels. Int Urol Nephrol 1996;28:55-9
27. Daniell HW. Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. J Urol 1993;149: 315-7
28. Giovannucci E, Rimm EB, Chute CG, Kawachi I, Colditz GA, Stampfer MJ, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994;140:989-1002
29. Kim JH, Shin BS, Hong YS. The relating factors of metabolic syndrome to benign prostatic hyperplasia. Korean J Urol 2005; 46:1046-50